Radio active Iodine in Thyroid Cancer

Q) Which of the following is not true about Radioactive Iodine (RAI) use in thyroid cancer? (Thyroid onco) 

a) Screening with RAI  is less sensitive than Thyroglobulin estimation in most differentiated thyroid cancers for detecting metastasis

b) Metastatic differentiated thyroid carcinoma can be detected by  131I in about 50% of patients

c) Current guidelines s recommend RAI after total thyroidectomy only for patients with known distant metastases

d) Hurthle cell cancer des not take up RAI

 

Bladder Cancer

Q) What is the most suitable treatment option for non muscle-invasive bladder cancer with the risk of recurrences?

A)Cystectomy

B)Intravesical chemotherapy

C)Transurethral resection and adjuvant intravesical chemotherapy

D)Palliative therapy

Answer-C(Schwartz-1654)

Patients with non–muscle-invasive bladder cancer (confined to the bladder mucosa or submucosa) can be managed with transurethral resection alone and adjuvant intravesical (instilled into the bladder) chemotherapy/immunotherapy.

The use of these intravesical agents is critical since patients with non–muscle-invasive bladder cancer are at risk for tumour recurrence and progression.

 

Uro Onco MCQS

TNM Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma TNM Staging MCQ | NEET SS Surgery
HEAD AND NECK SURGERY MCQ | NEET SS

Nasopharyngeal Carcinoma: TNM Staging

A 3.5 cm mass is identified in the nasopharynx, extending into the left nasal cavity. Imaging also reveals a 4.5 cm lymph node in the supraclavicular region. What is the correct TNM staging of this nasopharyngeal carcinoma?

A. T1N1
B. T1N3
C. T2N1
D. T2N3

Unlock the Answer and Detailed Explanation

Access detailed explanations, clinical scenario-based MCQs, image-based questions, mock tests and exam-focused surgery preparation resources with MCQSurgery.

Explore Premium Membership

Already a member? Log in to access premium content.

Nasopharyngeal Carcinoma TNM Staging: Important Exam Notes

Nasopharyngeal carcinoma is staged using the TNM system, which assesses the primary tumour (T), regional lymph nodes (N) and distant metastasis (M). Correct staging requires assessment of the anatomical extent of the primary lesion and the size, location and distribution of involved nodes.

Primary tumour classification

  • T1: Tumour confined to the nasopharynx or extending into the nasal cavity and/or oropharynx without parapharyngeal extension.
  • T2: Parapharyngeal extension and/or involvement of adjacent soft tissues.
  • T3: Involvement of skull base bone, cervical vertebrae, pterygoid structures or paranasal sinuses.
  • T4: Intracranial or cranial nerve involvement, orbital extension, hypopharyngeal involvement, parotid involvement or extensive soft-tissue disease.

Regional lymph node classification

Nodal staging considers the anatomical level of the involved nodes, their laterality, size and extension relative to defined anatomical landmarks. A 4.5 cm node does not qualify as N3 on size alone. The location must be assessed against the applicable staging criteria.

Important examination pearl

Extension into the nasal cavity alone is compatible with T1 disease. Do not upgrade to T2 without the relevant additional anatomical extension. Likewise, a description of a supraclavicular node should be interpreted using its precise anatomical location rather than its label alone.

Bevacizumab

Bevacizumab MCQ
Q) Not true about use of Bevacizumab
a) It is a humanized monoclonal antibody against VEGF A
b) Bevacizumab is a first-line treatment in metastatic nonsquamous non-small cell lung cancer.
c) Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer
d) Its major advantage is that it has replaced combination chemotherapy
Correct Answer: d) Its major advantage is that it has replaced combination chemotherapy
Explanation: a) True – Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis. b) True – Bevacizumab is used as first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). c) True – Bevacizumab is used as first-line and second-line therapy in combination with chemotherapy for metastatic colorectal cancer. d) Not true – Bevacizumab is not a replacement for combination chemotherapy. Instead, it is used in combination with standard chemotherapy regimens to improve efficacy. It is not used as a monotherapy in most settings.